Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.10.1056/NEJMoa1103782Search in Google Scholar

2. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.10.1016/S0140-6736(12)60868-XSearch in Google Scholar

3. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.10.1056/NEJMoa1210093Search in Google Scholar

4. Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol 2013; 24: 530-7.10.1093/annonc/mds292Search in Google Scholar

5. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368: 1365-6.10.1056/NEJMc1302338Search in Google Scholar

6. Rompoti N, Schilling B, Livingstone E, Griewank K, Hillen U, Sauerwein W, et al. Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J Clin Oncol 2013; 31: 3844-5.10.1200/JCO.2013.50.8473Search in Google Scholar

7. Ducassou A, David I, Delannes M, Chevreau C, Sibaud V. Radiosensitization induced by vemurafenib. Cancer Radiother 2013; 17: 304-7.10.1016/j.canrad.2013.04.004Search in Google Scholar

8. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 2008; 34: 232-40.10.1016/j.ejso.2007.05.016Search in Google Scholar

9. Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 2012; 99: 821-30.10.1002/bjs.8749Search in Google Scholar

10. Mir LG, L; Sersa, G; Collins, CG; Garbaya, GR; Billard, V; Geertsend, PF; et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Suppl 2006; 4: 14-25.10.1016/j.ejcsup.2006.08.003Search in Google Scholar

11. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J, Jr., Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 1993; 72: 3694-700.10.1002/1097-0142(19931215)72:12<3694::AID-CNCR2820721222>3.0.CO;2-2Search in Google Scholar

12. Matthiessen LW, Chalmers RL, Sainsbury DC, Veeramani S, Kessell G, Humphreys AC, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011; 50: 621-9.10.3109/0284186X.2011.573626Search in Google Scholar

13. Campana LG, Testori A, Mozzillo N, Rossi CR. Treatment of metastatic melanoma with electrochemotherapy. J Surg Oncol 2014; 109: 301-7.10.1002/jso.23512Search in Google Scholar

14. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2013; 39: 4-16.10.1016/j.ejso.2012.08.016Search in Google Scholar

15. Mali B, Miklavcic D, Campana LG, Cemazar M, Sersa G, Snoj M, et al. Tumor size and effectiveness of electrochemotherapy. Radiol Oncol 2013; 47: 32-41.10.2478/raon-2013-0002Search in Google Scholar

16. Gerlini G, Sestini S, Di Gennaro P, Urso C, Pimpinelli N, Borgognoni L. Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin Exp Metastasis 2013; 30: 37-45.10.1007/s10585-012-9505-1Search in Google Scholar

17. Sersa G, Kotnik V, Cemazar M, Miklavcic D, Kotnik A. Electrochemotherapy with bleomycin in SA-1 tumor-bearing mice--natural resistance and immune responsiveness. Anticancer Drugs 1996; 7: 785-91.10.1097/00001813-199609000-00011Search in Google Scholar

18. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18: 1386-94.10.1158/1078-0432.CCR-11-2479Search in Google Scholar

19. Schilling B, Paschen A. Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells. Oncoimmunology 2013; 2: e25218.10.4161/onci.25218Search in Google Scholar